According to the Zhitong Finance APP, BOYA BIOLOGY (300294.SZ) announced that in order to enhance the supply capacity of raw plasma, strengthen market competitiveness, and deepen strategic cooperation with related parties, the company plans to jointly invest with related party Chengdu Hengnashun Enterprise Management Consulting Co., Ltd. (hereinafter referred to as Chengdu Hengnashun) to establish Dalateqi Boya Plasma Collection Co., Ltd. (the final name is subject to industrial and commercial registration, hereinafter referred to as the target company).

Chengdu Hengnashun is funded by Shenzhen Gaotejia Runhua Investment Co., Ltd. (hereinafter referred to as Gaotejia Runhua) with an investment of 1.2 million yuan, accounting for 60%; and Hu Guobin with an investment of 800,000 yuan, accounting for 40%. Shenzhen Gaotejia Investment Group Co., Ltd. (hereinafter referred to as Gaotejia Group) holds a controlling stake in Gaotejia Runhua and indirectly controls Chengdu Hengnashun. Gaotejia Group holds 11.31% of the company's shares, thus Chengdu Hengnashun is a related party of the company.

This joint investment with related parties to establish a company marks an important milestone in the cooperation between the company and Gaotejia Group. By integrating resources from both sides, the two parties will further deepen cooperation in the plasma collection business and related fields in the future, fully leverage their respective advantages, achieve mutual benefits and win-win results, and lay a solid foundation for the company's long-term development in the blood products market